(Q24187867)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

0 references

1 reference

title

Belatacept for kidney transplant recipients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Angela Webster

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Philip Masson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Lorna Henderson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Jeremy R Chapman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

24 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

CD010699

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Beneficial effect of belatacept on health-related quality of life and perceived side effects: results from the BENEFIT and BENEFIT-EXT trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

An integrated safety profile analysis of belatacept in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Five-year safety and efficacy of belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Costimulation blockade with belatacept in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Malignancy after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

The new BMJ policy on sharing data from drug and device trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Consistency and completeness of reported outcomes in randomized trials of primary immunosuppression in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

The alphabet soup of kidney transplantation: SCD, DCD, ECD--fundamentals for the practicing nephrologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

The role of T-cell costimulatory activation pathways in transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Managing cancer risk and decision making after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Use of kidney function end points in kidney transplant trials: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Belatacept for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010699.PUB2

Risk factors for cardiovascular events after successful renal transplantation

21 January 2018

1 reference

12 December 2020

De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure

1 reference

12 December 2020

Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation

1 reference

12 December 2020

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

1 reference

12 December 2020

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies

1 reference

12 December 2020

High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment

1 reference

12 December 2020

Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients

1 reference

12 December 2020

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)

1 reference

12 December 2020

Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys

1 reference

12 December 2020

Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study

1 reference

12 December 2020

10.1002/14651858.CD010699.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

1256075

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1256075

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

25416857

2 references

Consolidated OpenCitations Corpus – April 2017

1256075

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25416857%20AND%20SRC:MED&resulttype=core&format=json